As per this study the Global Oncology Biomarker Market was valued USD XX.X BN (by revenue) in 2019 and is anticipated to reach USD 28 BN by 2026 with a CAGR of XX.X%.
A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer. Oncology biomarkers are the biomolecules that are secreted only by tumor cells that leads to diagnosis or prognosis of cancer. Oncology biomarker includes protein, muted genes, DNA, mRNA, and metabolites that aids in the diagnosis of cancer.
Growing count of the population suffering from various types of cancer has created demand of biomarkers leading to early diagnosis and prognosis of cancer. Increase funding by government for cancer diagnosis technique and treatment is fueling the market growth. Owing to a non-invasive method for cancer detection followed by increased cancer awareness is boosting the market growth. In spite of this advantage, high cost associated with diagnosis is restraining the market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of oncology biomarker.
The broad oncology biomarker market has been sub-grouped into profiling technology, biomolecule, cancer type, and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Profiling Technology
- Omics Technology
- Other Omics Technologies
- Imaging Technology
- Cytogenetic-Based Tests
By Cancer Type
- Genetic Biomarkers
- Protein Biomarkers
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Drug Discovery And Development
- Risk Assessment
Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for oncology biomarker in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Europe Oncology Biomarker Market By Revenue (USD MN)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the oncology biomarker market include Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc. and Qiagen N.V. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.